
Overview
Through cancer trials, doctors hope to find new ways to improve patients’ cancer treatments and quality of life. Clinical trials provide access to innovative and experimental therapies to patients with solid and circulating tumors, including through the National Cancer Institute’s Clinical Trials Network (NCTN). Our centralized clinical research team is comprised of research nurses, data managers, and regulatory coordinators.
Investigative research, provides the ability to identify, develop and study new innovations in a real health system setting. While cancer care has already made tremendous progress, further innovation and research is necessary to develop and implement the next generation of therapeutics, best practices and disease prevention and targeted treatments targeted to the precise needs of the patient.
As part of the AdventHealth Oncology Research program In the Rocky Mountain Region we can access clinical trials that lead to investigational treatments and experiential cancer therapies.
Our research is conducted by our dedicated team of physicians determined to find the effectiveness of a new drugs or technology in a real-world setting. Investigational treatments provide patients with additional treatment options otherwise not available while contributing to cancer research.
For more information on current clinical trials, patient eligibility and other considerations, call us at Call303-765-6775.
Areas of Focus
- Bladders
- Breast
- Esophageal
- Multiple Myeloma
- Neuroendocrine
- Urologic
Meet the Team

Nadine Mikhaeel-Kamel, MD

Yousuf Gaffar, MD
Physician

Mohammed Salhab, MD

Jose Pacheco, MD
Featured Clinical Trials
-
NCT05929768
S2212, SHORTER ANTHRACYCLINE-FREE CHEMO IMMUNOTHERAPY ADAPTED TO PATHOLOGICAL RESPONSE IN EARLY TRIPLE NEGATIVE BREAST CANCER (SCARLET), A RANDOMIZED PHASE III STUDY
This study is currently enrolling.Research Area: Rocky Mountain Cancer ResearchThis is a randomized Phase III trial comparing a standard neoadjuvant chemotherapy regimen to an experimental neoadjuvant chemotherapy regimen that omits AC therapy. Both arms receive pembrolizumab...
-
NCT04248452
EA2183, A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
This study is currently enrolling.Research Area: Rocky Mountain Cancer ResearchThis phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric...
-
NCT04071457
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
This study is currently enrolling.Research Area: Rocky Mountain Cancer ResearchPatients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first...
More clinical trials loaded